Paris, July 31, 2013

"Press Release"

Results to end-June 2013

Group operating performance proves resilient
against a backdrop of falling rates

  • Reported turnover was down 3.2%, with two fewer working days, and stable on a like-for-like basis (edging up 0.3%) 

  • Reported EBITDA declined slightly by 5.4%, while the EBITDA rate was stable (14% vs. 14.4% in H1 2012) 

  • Current operating profit contracted 8.1%, while net income attributable to the parent also fell  

  • Reported turnover was down 3.2% at end-June 2013. 

On a like-for-like basis, turnover edged up slightly by 0.3% vs. the first half of 2012, hampered by two fewer working days. The Group saw the number of acute-care stays fall back 0.8%, with 441,000 stays on a like-for-like basis (excluding emergency care),

  • EBITDA stood at ?137.8 million, down 5.4%. 

EBITDA declined slightly, penalized by restrictive government measures,

  • Reported current operating profit was ?76.5 million as at June 30, 2013, down from ?83.2 million in 2012. 

Pascal Roché, the Group's Chief Executive Officer, said:

"Générale de Santé's H1 2013 results show resilience, despite a challenging environment and a negative calendar impact (two fewer working days). On a like-for-like basis, and in a context of falling rates since March 1, 2013, our turnover has remained stable, edging up 0.3% to ?978.9 million. EBITDA was robust (up 14% vs. 14.4% in H1 2012), reflecting a tight cost control. Emergency room visits rose significantly, by around 5% (to 201,000), while medical practitioners-surgery-obstetrics contracted slightly (down 0.8%), as a result of the impact of the financial crisis on hospital activity. Under the Group's investment program, which aims to constantly improve its medical, surgery and obstetrics care offering throughout France, seven facilities were opened in 2012. In addition, since January 1, 2013, a new radiotherapy center opened its doors at the Hôpital Privé des Peupliers, and the Hôpital Privé de l'Ouest Parisien was extended. These developments will support the Group in its policy of continuous improvement in its healthcare offering."

In ? millions End of June 2013 Change End of June 2012
Revenue 982.1 -3.2% 1,014.1
EBITDA 137.8 -5.4% 145.7
Current operating profit 76.5 -8.1% 83.2
As a % of revenue7.8%-0.4 point8.2%
Operating profit 66.7 -14.6% 78.1
Net income attributable to the Group 26.8 -4.6% 28.1
Net profit per share (in ?) 0.47 -6.0% 0.50

Business - Fall in reported turnover

H1 2013 consolidated turnover was down 3.2% to ?982.1 million from ?1,014.1 million in the first half of 2012. Stripping out changes in scope, turnover rose a slight 0.3% in the period.

In ? millions - 2013
End of June
2012
End of June
2013/2012 change Q2 2013 Q2 20122013/2012 change
Ile de France 406.5 407.6 - 0.3% 201.8 200.1 + 0.8%
Rhône Alpes 154.4 153.5 + 0.6% 76.2 74.4 + 2.4%
Nord 102.8 102.8 -- 51.2 50.5 + 1.4%
Provence Alpes Côte d'Azur 96.1 95.7 + 0.4% 47.4 46.4 + 2.2%
Bourgogne 59.2 57.5 + 3.0% 29.3 27.7 + 5.8%
Other regions 144.8 140.4 + 3.1% 72.3 69.9 + 3.4%
Other activities (1) 18.3 56.6 - 67.7% 4.6 27.6 - 83.3%
Published revenue 982.1 1,014.1 - 3.2% 482.8 496.6- 2.8%
Of which:    - Organic 978.9 976.4 + 0.3% 482.3 473.5 + 1.9%
               inc. organic France966.5964.4+ 0.2%476.0467.6+ 1.8%
               inc. organic Italy12.412.0+ 3.3%6.35.9+ 6.8%
              Change in consolidation scope 3.2 37.7 N/S 0,5 23.1 N/S
  1. "Other Activities" include non-strategic activities whose assets have been sold 

In France, the changes in scope stem from the disposal of the Charleville-Mézières and Saint Martin - Pessac facilities in July and August, 2012 as well as from the disposal of the Hôpital Privé Beauregard in May 2013.

Hospital Care and Services in France saw limited organic growth of 0.2% in the first half of 2013, reined in by the contraction in our volumes.

During the first half of 2013, medical, surgery and obstetrics services (MSO) in the Group's hospitals edged down 0.8% on a like-for-like basis vs. H1 2012, to 441,000 stays. This decline affected surgery (-0.3%), medical (-0.4%) and obstetrics (-4.3%).

In terms of the Group's public service function, the number of emergency care treatments rose 4.8% at end-June 2013, with 201,000 visits to our emergency rooms.

In the area of mental health, the Group saw a 2.7% increase in the number of days invoiced in the period (to 457,000 at end-June 2013), achieved in part through continued higher occupancy rates, but particularly attributable to the steady increase in openings and expansions in several establishments.

The opening of two mental health facilities (Clinique du Pont de Gien and the specialist care home Maison d'accueil spécialisée du Vendômois) in the Centre region of France (45), the extension to the emergency room at the Hôpital Privé d'Antony (92) and the opening of the Radiotherapy Center at the Hôpital Privé des Peupliers in Paris (75) all attest to the Group's commitment to continue investing in the expansion of its healthcare offering throughout France and are set to support growth in 2013 and subsequent years.

Organic turnover in Italy is generated solely from activity at the Hôpital d'Omegna, which recorded growth of 3.3% at end-June 2013.

Results:

1) Contraction in current operating profit

The Group's EBITDA contracted 5.4% in the first half, linked to the decline in reported turnover (down 3.2%), and primarily due to the rise in property rental expenses and a negative scissors effect produced by higher costs.

Current operating profit also trended downward by 8.1% to ?76.5 million.

2) Stable net income

Operating profit amounted to ?66.7 million at June 30, 2013, versus ?78.1 million the previous year.

Net income fell slightly to ?26.8 million, helped by the reduction in the cost of debt and tax expense.

Debt: seasonal rise in net financial debt under IFRS at end-June 2013 to ?810.4 million (from ?769.1 million at end-December 2012), but down compared with June 2012 (?847.2 million)

Net financial debt under IFRS rose from the end of December 2012 to reach ?810.4 million, driven up by the usual seasonal variation in the Group's surplus working capital between December and June. The debt includes ?581.1 million in borrowing and long-term financial debts, ?194.7 million in short-term financial debts and ?32.8 million in bank overdrafts.

The interim accounts have been the subject of a limited review by the company's auditors.

Générale de Santé, listed on the Euronext Paris Eurolist (formerly known as the Premier Marché) since June 2001, is included in the Midcac index. The leading private healthcare and services group, Générale de Santé has 19,400 employees, including 7,000 nurses and 4,100 care staff, in 103 private facilities, clinics and hospitals. With 5,050 practitioners, it is the leading independent medical community in France. As a major player in hospital care, Générale de Santé covers the entire healthcare chain: medical, surgery and obstetrics, oncology, after-care and rehabilitation, mental health and home medical services.  Générale de Santé has developed a unique healthcare offering, combining quality and safety of care, efficient organization and a human touch. The Group offers comprehensive care with personalized support before, during, and after hospitalization, taking into account all aspects of the patient's needs; it also operates in the public health service and national healthcare network.

ISIN and Euronext Paris code: FR0000044471
Website: www.generale-de-sante.fr:
http://www.generale-de-sante.fr/

Conference call in English today

at 18:00 (Paris time) - dial:

From France:                 +33 (0) 1 56 38 35 00
From Italy:       +39 (0) 0645210 8002
From the UK     +44 (0) 207 154 2667
From the United States:   +1 (0) 480 248 5061

Next key date:

Publication of Q3 2013 financial statements

 

 

Investor/Analyst relations:
Arnaud Jeudy
Tel. + 33 (0)1 53 23 14 75
a.jeudy@gsante.fr  
Media relations:
Martine Esquirou
Tel. + 33 (0)1 53 23 12 62
m.esquirou@gsante.fr
Guillaume Jubin
Tel. +33 (0)1 44 14 99 99
g.jubin@tilder.com

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
1st half
( in million euros ) 2012 2012 2013
TURNOVER 1,928.6 1,014.1 982.1
Personnel expenses and profit sharing   (873.5) (448.7) (429.9)
Purchased consumables   (362.0) (193.2) (179.5)
Other operating income and expenses   (214.5) (105.9) (111.8)
Taxes and duties   (85.1) (43.2) (43.2)
Rents   (153.8) (77.4) (79.9)
EBITDA 239.7 145.7 137.8
Depreciation   (124.5) (62.5) (61.3)
Current operating profit 115.2 83.2 76.5
Restructuring costs   (10.4) (3.0) (5.4)
Result of the management of real estate and financial assets   29.5 (2.1) (4.4)
Impairment of goodwill   -- -- --
Other non current income and expenses        19.1 (5.1) (9.8)
Operating profit 134.3 78.1 66.7
Gross interest expenses   (33.3) (17.2) (15.1)
Income from cash and cash equivalents   0.5 0.3 0.2
Net interest expenses   (32.8) (16.9) (14.9)
Other financial income   0.4 0.1 0.1
Other financial expenses   (6.3) (3.9) (2.6)
Other financial income and expenses   (5.9) (3.8) (2.5)
Corporate income tax   (36.5) (26.1) (19.0)
Share of net profit of associates   0.2 -- --
NET PROFIT FOR THE PERIOD   59.3 31.3 30.3
Revenues and expenses recognised directly as equity      
- Retirement commitments   (1.7) --- ---
- Change in fair value of hedging financial instruments   0.6 (1.5) 5.6
- Translation differential        -- --- ---
- Income tax on other comprehensive income   (0.1) 0.5 (2.0)
Results recognised directly as equity   (1.2) (1.0) 3.6
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 58.1 30.3 33.9
1st half
PROFIT ATTRIBUTABLE TO (in million euros) 2012 2012 2013
Group's share of net earnings        55.7 28.1 26.8
Non-controlling interests   3.6 3.2 3.5
NET PROFIT FOR THE PERIOD 59.3 31.3 30.3
NET EARNINGS PER SHARE  (in euros) 0.99 0.50 0.47
NET DILUTED EARNINGS PER SHARE (in euros) 0.99 0.50 0.47
1st half
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO (in million euros) 2012 2012 2013
Group's comprehensive income for the period        54.5 27.1 30.4
Non-controlling interests   3.6 3.2 3.5
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 58.1 30.3 33.9

CONSOLIDATED BALANCE SHEET - ASSETS
( in million euros ) 12-31-2011 12-31-2012 06-30-2013
Goodwill   569.0 562.2 562.1
Other intangible fixed assets   18.6 19.0 18.7
Tangible fixed assets   863.5 809.8 771.7
Investments in associates   0.1 0.5 0.3
Other long-term investments   29.2 35.7 34.0
Deferred tax assets   48.4 44.5 37.1
NON CURRENT ASSETS 1,528.8 1,471.7 1,423.9
Inventories   34.6 33.2 32.8
Trade and other receivables   120.3 121.5 137.5
Other current assets   155.5 138.1 174.4
Current tax assets   6.1 2.5 6.4
Current financial assets   7.3 4.4 4.6
Cash and cash equivalents   --- --- ---
Assets held for sale   3.7 1.5 2.3
CURRENT ASSETS 327.5 301.2 358.0
TOTAL ASSETS 1,856.3 1,772.9 1,781.9

CONSOLIDATED BALANCE SHEET - LIABILITIES AND EQUITY
( in million euros ) 12-31-2011 12-31-2012 06-30-2013
Share capital   42.3 42.3 42.3
Additional paid-in capital   64.6 64.6 64.6
Consolidated reserves   283.5 211.5 224.3
Group's share of net profit   (28.5) 55.7 26.8
Group's share of equity 361.9 374.1 358.0
Non-controlling interests   12.4 12.2 14.2
TOTAL SHAREHOLDERS' EQUITY 374.3 386.3 372.2
Borrowings and financial debts   688.1 620.1 581.1
Provisions for retirement and other employee benefits   29.7 33.4 34.0
Non-current provisions   42.2 34.8 32.4
Other long term liabilities   32.9 24.9 17.7
Deferred tax liabilities   78.9 70.2 69.6
NON CURRENT LIABILITIES 871.8 783.4 734.8
Current provisions   11.2 8.9 9.3
Accounts payable   128.1 159.2 173.8
Other current liabilities   305.7 287.8 260.5
Tax liabilities due   2.0 3.9 3.8
Short-term borrowings   137.5 133.1 194.7
Bank overdraft   25.7 10.3 32.8
Liabilities related to assets held for sale   --- --- ---
CURRENT LIABILITIES 610.2 603.2 674.9
TOTAL EQUITY AND LIABILITIES 1,856.3 1,772.9 1,781.9

consolidated statement of changes in equity
( in million euros ) SHARE CAPITAL ADDITION AL PAID IN CAPITAL RESERVES RESULTS RECOGNISED DIRECTLY AS EQUITY TOTAL COMPREHENSIVE INCOME FOR THE PERIOD GROUP'S SHARE OF EQUITY NON CONTROLLING INTERESTs SHAREHOLDERS' EQUITY
Shareholders' equity at December 31,  2011 42.3 64.6 295.7 (12.2) (28.5) 361.9 12.4 374.3
Capital increase (including net fees)        -- -- -- -- -- -- -- --
Treasury shares        -- -- -- -- -- -- -- --
Stocks options and free share        -- -- -- -- -- -- -- --
Prior year appropriation of earnings        -- -- (28.5) -- 28.5 -- -- --
Distribution of dividends        -- -- (42.3) -- -- (42.3) (3.2) (45.5)
Change in consolidation scope        -- -- -- -- -- -- (0.6) (0.6)
Total comprehensive income for the period   -- -- -- (1.2) 55.7 54.5 3.6 58.1
Shareholders' equity at December 31,  2012 42.3 64.6 224.9 (13.4) 55.7 374.1 12.2 386.3
Capital increase (including net fees)        -- -- (4.2) -- -- (4.2) -- (4.2)
Treasury shares        -- -- -- -- -- -- -- --
Stocks options and free share        -- -- -- -- -- -- --
Prior year appropriation of earnings        -- -- 55.7 -- (55.7) -- -- --
Distribution of dividends        -- -- (42.3) -- -- (42.3) (1.5) (43.8)
Change in consolidation scope        -- -- -- -- -- -- - --
Total comprehensive income for the period   -- -- -- 3.6 26.8 30.4 3.5 33.9
Shareholders' equity at June 30, 2013 42.3 64.6 234.1 (9.8) 26.8 358.0 14.2 372.2
12-31-2011 12-31-2012 06-30-2013
Dividends per share (in euros including pre-distribution)   1.00 0.75 0.75
Number of treasury shares   25 301 25 301 25 301

revenues and expenses recognised directly as equity
( in million euros ) 12-31-2011 Income and expenses 2012 12-31-2012 Income and expenses
1st half 2013
06-30-2013
Translation differential   (0.3) -- (0.3) -- (0.3)
Retirement commitments   (1.2) (1.6) (2.8) -- (2.8)
Fair value of hedging financial instruments   (10.7) 0.4 (10.3) 3.6 (6.7)
Results recognised directly as equity (Group's share) (12.2) (1.2) (13.4) 3.6 (9.8)

CONSOLIDATED CASH FLOW STATEMENT
( in million euros ) 2012 1st half
2012 2013
Total net consolidated profit        59.3 31.3 30.3
Depreciation   124.5 62.5 61.3
Other non current income and expenses   (19.1) 5.1 9.8
Share of net profit of associates   (0.2) -- --
Other financial income and expenses   5.9 3.8 2.5
Net interest expenses   32.8 16.9 14.9
Corporate income tax   36.5 26.1 19.0
EBITDA 239.7 145.7 137.8
Non cash items including provisions and reversals (transactions with no cash effect)   (1.4) -- 1.8
Other income and expenses paid   (23.0) (12.4) (8.5)
Changes in other long term assets and liabilities   (4.3) (1.6) (0.7)
Cash flow before net interest expenses & taxes 211.0 131.7 130.4
Corporate income tax paid   (36.3) (8.9) (16.3)
Change in working capital requirements   32.0 0.3 (39.5)
NET CASH FROM OPERATING ACTIVITIES   : (A) 206.7 123.1 74.6
Purchase of property, plant & equipment and intangible assets   (55.3) (32.5) (46.3)
Proceeds from sale of tangible and intangible assets   10.0 -- --
Purchase of financial assets   (7.0) (5.7) --
Proceeds from the disposal of financial assets   40.3 (0.5) 3.8
Dividends from non consolidated companies   0.4 0.1 --
NET CASH USED FOR INVESTING ACTIVITIES  :  (B) (11.6) (38.6) (42.5)
Capital increase: (a)   --- -- (4.2)
Capital increase performed by subsidiaries subscribed to by third parties (b)   --- -- --
Exceptional distribution of additional paid-in capital (c)   --- -- --
Dividends paid to GDS shareholders: (d)   (42.3) -- --
Dividends paid to minority interests of consolidated companies: (e)   (3.2) (1.1) (1.5)
Net interest expense paid : (f)   (32.8) (16.9) (14.9)
Debt issue costs : (g)   --- -- --
Cash flow before repayment of borrowings: (h) = (A+B + a + b + c + d + e + f + g) 116.8 66.5 11.5
Increase in borrowings : (i)   25.0 25.0 15.0
Repayment of borrowings : (j)   (126.4) (68.2) (49.0)
NET CASH USED FOR  FINANCING ACTIVITIES: (C) = a + b + c + d + e + f + g + i + j (179.7) (61.2) (54.6)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS: ( A + B + C ) 15.4 23.3 (22.5)
Reclassification of the cash of the assets held for sale   --- --- ---
Cash and cash equivalents at beginning of period   (25.7) (25.7) (10.3)
Cash and cash equivalents at end of period   (10.3) (2.4) (32.8)
Net indebtedness at beginning of period 854.4 854.4 769.1
Cash flow before repayment of borrowings: (h)   (116.8) (66.5) (11.5)
Capitalization of financial leases   32.8 11.8 7.6
Loan issue charges fixed assets   3.5 1.8 1.8
Assets held for sale   (2.2) 1.0 0.8
Fair value of financial hedging instruments   (0.4) 1.0 (3.6)
Dividends to pay   --- 42.3 42.3
Change in scope of consolidation and other   (2.2) 1.4 3.9
Net indebtedness at end of period 769.1 847.2 810.4
GENERALE DE SANTE : 2013 SECOND QUARTER REVENUE:
http://hugin.info/143423/R/1720123/572579.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: GENERALE DE SANTE via Thomson Reuters ONE

HUG#1720123